TABLE 5.
Subgroup analysis using potential confounders as the stratification variables
| AAPR Tertile | N | Low | Medium | P value | High | P value | P value for tread |
|---|---|---|---|---|---|---|---|
| Age | |||||||
| <65 | 577 | 1.0 | 0.78 (0.60, 1.00) | .0477 | 0.68 (0.54, 0.87) | .0020 | .002 |
| ≥65 | 231 | 1.0 | 0.77 (0.52, 1.16) | .2109 | 0.44 (0.29, 0.66) | <.0001 | <.0001 |
| Gender | |||||||
| Male | 556 | 1.0 | 0.78 (0.61, 0.99) | .0433 | 0.58 (0.45, 0.75) | <.0001 | <.0001 |
| Female | 252 | 1.0 | 0.88 (0.58, 1.33) | .5479 | 0.76 (0.54, 1.09) | .1355 | .1330 |
| Smoking history | |||||||
| Never | 383 | 1.0 | 0.74 (0.53, 1.02) | .0637 | 0.56 (0.42, 0.75) | <.0001 | <.0001 |
| Ever | 413 | 1.0 | 0.83 (0.62, 1.11) | .2058 | 0.71 (0.53, 0.96) | .0265 | .0260 |
| Uncertain | 11 | 1.0 | 0.57 (0.11, 2.90) | .4957 | 0.82 (0.17, 3.99) | .8012 | .8608 |
| ECOG | |||||||
| 0‐1 | 654 | 1.0 | 0.84 (0.66, 1.07) | .1646 | 0.63 (0.50, 0.80) | .0001 | <.0001 |
| ≥2 | 93 | 1.0 | 0.79 (0.45, 1.41) | .4328 | 0.81 (0.47, 1.40) | .4601 | .4359 |
| Pathology | |||||||
| Adenocarcinoma | 592 | 1.0 | 0.84 (0.66, 1.08) | .1825 | 0.63 (0.50, 0.80) | .0002 | .0002 |
| Squamous cell carcinoma | 189 | 1.0 | 0.68 (0.43, 1.06) | .0893 | 0.49 (0.31, 0.77) | .0021 | .0023 |
| Others | 27 | 1.0 | 0.15 (0.04, 0.51) | .0024 | 0.35 (0.11, 1.04) | .0592 | .2482 |
| Clinical stage | |||||||
| IIIA + IIIB | 120 | 1.0 | 0.89 (0.44, 1.82) | .7579 | 0.81 (0.40, 1.62) | .5516 | .5338 |
| IV | 688 | 1.0 | 0.84 (0.67, 1.05) | .1308 | 0.63 (0.51, 0.78) | <.0001 | <.0001 |
| Bone | |||||||
| No | 504 | 1.0 | 0.71 (0.54, 0.95) | .0191 | 0.50 (0.38, 0.66) | <.0001 | <.0001 |
| Yes | 284 | 1.0 | 0.89 (0.64, 1.25) | .5057 | 0.85 (0.59, 1.24) | .4104 | .3665 |
| Liver | |||||||
| No | 672 | 1.0 | 0.84 (0.67, 1.06) | .1415 | 0.63 (0.50, 0.80) | <.0001 | <.0001 |
| Yes | 116 | 1.0 | 0.80 (0.44, 1.44) | .4546 | 0.58 (0.34, 0.98) | .0434 | .0423 |
| Lung | |||||||
| No | 488 | 1.0 | 0.80 (0.61, 1.05) | .1026 | 0.63 (0.48, 0.82) | .0007 | .0007 |
| Yes | 300 | 1.0 | 0.83 (0.58, 1.17) | .2821 | 0.58 (0.42, 0.82) | .0018 | .0017 |
| Brain | |||||||
| No | 644 | 1.0 | 0.79 (0.63, 1.01) | .0557 | 0.57 (0.45, 0.71) | <.0001 | <.0001 |
| Yes | 144 | 1.0 | 0.84 (0.51, 1.38) | .4905 | 0.89 (0.54, 1.44) | .6247 | .6128 |
| Pleural effusion | |||||||
| No | 489 | 1.0 | 0.88 (0.68, 1.15) | .3598 | 0.66 (0.50, 0.86) | .0019 | .0019 |
| Yes | 299 | 1.0 | 0.68 (0.48, 0.97) | .0315 | 0.53 (0.38, 0.75) | .0003 | .0004 |
| Number of organ metastasis | |||||||
| ≤3 | 428 | 1.0 | 0.71 (0.52, 0.98) | .0343 | 0.57 (0.43, 0.77) | .0002 | .0002 |
| >3 | 360 | 1.0 | 0.93 (0.70, 1.25) | .6426 | 0.69 (0.50, 0.96) | .0277 | .0333 |
| EGFR | |||||||
| Negative | 204 | 1.0 | 0.77 (0.51, 1.16) | .2133 | 0.49 (0.31, 0.76) | .0017 | .0016 |
| Positive | 137 | 1.0 | 0.68 (0.37, 1.24) | .2069 | 0.67 (0.36, 1.22) | .1897 | .1696 |
| Unknown | 467 | 1.0 | 0.80 (0.61, 1.05) | .1158 | 0.60 (0.46, 0.77) | <.0001 | <.0001 |
| ALK | |||||||
| Negative | 299 | 1.0 | 0.88 (0.62, 1.25) | .4697 | 0.64 (0.44, 0.93) | .0199 | .0211 |
| Positive | 29 | 1.0 | 1.12 (0.34, 3.68) | .8569 | 0.45 (0.06, 3.55) | .4477 | .5637 |
| Unknown | 480 | 1.0 | 0.69 (0.53, 0.91) | .0088 | 0.55 (0.42, 0.71) | <.0001 | <.0001 |
| First‐line regiment | |||||||
| Platinum‐based doublet chemotherapy | 409 | 1.0 | 0.80 (0.59, 1.08) | .1404 | 0.62 (0.46, 0.82) | .0008 | .0008 |
| Single drug chemotherapy | 36 | 1.0 | 1.27 (0.47, 3.41) | .6411 | 0.75 (0.24, 2.34) | .6187 | .5822 |
| Targeted therapy | 125 | 1.0 | 0.77 (0.43, 1.38) | .3745 | 0.83 (0.50, 1.39) | .4804 | .4800 |
| Platinum‐based doublet chemotherapy plus angiogenesis‐therapy | 49 | 1.0 | 1.34 (0.44, 4.05) | .6023 | 0.55 (0.20, 1.52) | .2487 | .1697 |
| Number of treatment lines | |||||||
| ≤3 | 488 | 1.0 | 0.74 (0.56, 0.98) | .0372 | 0.55 (0.42, 0.72) | <.0001 | <.0001 |
| >3 | 146 | 1.0 | 1.46 (0.85, 2.51) | .1733 | 1.17 (0.69, 1.97) | .5559 | .5988 |